Profile: Optimer Pharmaceuticals Inc (OPTR.OQ)

OPTR.OQ on NASDAQ Stock Exchange Global Select Market

12.48USD
1 Aug 2013
Price Change (% chg)

$-0.03 (-0.24%)
Prev Close
$12.51
Open
$12.64
Day's High
$12.65
Day's Low
$12.48
Volume
558,582
Avg. Vol
327,918
52-wk High
$16.77
52-wk Low
$8.66

Search Stocks

Optimer Pharmaceuticals, Inc. (Optimer), incorporated on November 18, 1998, is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company’s development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer’s products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. In January 2011, its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD).

Anti-Infectives Product Candidates

The Company is developing fidaxomicin for the treatment of infections caused by Clostridium difficile (C. difficile) bacteria. C. difficile is the common cause of infectious diarrhea in healthcare settings. Fidaxomicin is an antibacterial drug for the treatment of CDAD in adults above 18 years of age. Oral vancomycin is used in the United States and also in Europe and Japan for the treatment of CDAD. The Company has completed two fidaxomicin Phase III trials, which provided the basis for marketing approvals in the United States and European Union, and its marketing application Canada. Components of its OPopS technology are GlycoOptimization and De Novo Glycosylation.

Other Pipeline Product Candidates Product Candidates

Macrolide antibiotics have been marketed for the treatment of upper and lower respiratory tract infections. Macrolides, such as erythromycin and azithromycin, and ketolides, such as telithromycin, are related classes of antibiotics, which have gram-positive activity and inhibit bacterial growth. The product candidate developed with the Company’s discovery technology, including glycooptimization, CEM-101 (OP-1068), was effective against these resistant bacterial strains. This product candidate has an activity against multi-drug resistant Streptococcus pneumoniae and Streptococcus pyogenes, common RTI pathogens. The pre-clinical study also showed that CEM-101 was orally active in animal models.

Cempra Pharmaceuticals, Inc. (Cempra) has licensed from the Company a library of approximately 500 macrolides related to this product candidate. OBI is developing OPT-822/821 for the treatment of metastatic breast cancer. OPT-822/821 is a cancer immunotherapy and is composed of Globo H linked to a protein carrier.

The Company competes with Pfizer, Sanofi-Aventis, Viropharma, Salix, Nanotherapeutics, Merck and Cubist.

Company Address

Optimer Pharmaceuticals Inc

Suite 3501, 101 Hudson Street
JERSEY CITY   NJ   07302
P: +1201.3338819
F: +1201.3338870

Search Stocks